Terns Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Terns Pharmaceuticals

12/11/2024 23:15

* Terns Pharmaceuticals Inc  TERN.OQ  reported a quarterly
adjusted loss of 28 cents​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -42 cents.  The mean expectation of
ten analysts for the quarter was for a loss of 32 cents per
share. Wall Street expected results to range from -37 cents
to -30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Terns Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 28 cents​.
    * The company reported a quarterly loss of $21.95 million.
    * Terns Pharmaceuticals Inc shares had fallen by 10.6% this
quarter and gained 14.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Terns
Pharmaceuticals Inc is 18.00 
This summary was machine generated from LSEG data November 12 at
11:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.32          -0.28          Beat
 Jun. 30 2024      -0.34          -0.31          Beat
 Mar. 31 2024      -0.34          -0.30          Beat
 Dec. 31 2023      -0.29          -0.29          Met